PDA

View Full Version : IGXT ... IntelGenx



DennisWef
07-14-2015,
This is a real once in a lifetime opportunity ..GLTA

Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by in 2013 because of its very low burn-rate of just $1.2 Mil a year !

IGXT Submits next NDA to the FDA for an Anti-Migraine Versafilm last Week and another 3x More NDA/ANDA filings expected in 1H 2013. This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .


IGXT has NO DEBT and current Market cap of just $32 M is really a BIG BIG BARGAIN .

My Target is $8-12 within 2 Years .GLTA


Intelgenx (IGXT)

Market Cap : $32 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year

Price : $0.63

Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)


"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.

March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.



HUGE Prodcut Pipeline
http://wsw.com/webcast/roth27/igxt/2__Slide6.JPG


Upcoming Milestones
http://wsw.com/webcast/roth27/igxt/2__Slide19.JPG


New Presentation March 2013
http://de.slideshare.net/ViralNetwor...sentation-2012


Big Buying by Institutions
http://finance.yahoo.com/q/it?s=IGXT...r+Transactions

DennisEn
07-14-2015,
Analyst Coverage:

IGXT gets 18 month $3.00 Price Target from AEGIS CAPITAL CORP on October 5th, 2012
http://image.slidesharecdn.com/aegis...phpapp01/95/sl
ide-1-1024.jpg?1349900345

Cleland shares the names of a handful of small companies that could return tenfold or greater multiples to investors.
http://www.thelifesciencesreport.com/pub/na/14076

TLSR: What types of healthcare companies are you looking for? Do you lean toward specialty pharma, where you can monetize more quickly? What are your preferences?

I have at least two investments in this area—is in the FDA's 505(b)(2) pathway, also known as the rapid approval route. This pathway can be used by companies taking an existing drug with hundreds of millions or several billion dollars in sales and porting that drug onto a different delivery technology. Biovail Corp. (now part of Valeant Pharmaceuticals International Inc. [VRX:NYSE]) followed this pathway when it made Wellbutrin XL, a one-a-day version of Wellbutrin (bupropion hydrochloride). IntelGenx (IGX:TSX.V; IGXTTCQX) is my poster child in this area, with eight drugs in various stages of the 505(b)(2) approval process, and one 505(b)(2) drug that will be commercially launched this fall, having received FDA approval in November 2011.

TLSR: What's the next company you'd like to talk about?

HC: IntelGenx is the company through which I learned about the 505(b)(2) pathway, and why that pathway is so attractive to me. It's a drug delivery company that takes existing, commercialized drugs and ports them onto different delivery modalities, making them better from a patient compliance perspective or from a time-to-onset-of-action perspective. The existing drugs the company is working with have commercial revenues in the hundreds of millions to several billion-dollar range.

IntelGenx is about to launch its antidepressant drug, having received FDA approval in November 2011, and has a pipeline of eight drugs being developed via the 505(b)(2) pathway. The company is a table-pounder, simply on the basis that it has an approved drug and a market cap of only $30M. It is truly one of the most dramatic valuation disconnects that I am aware of. Full disclosure: Funds that I manage control about 12% of the company.

A migraine drug called rizatriptan is a good example of one of IntelGenx's pipeline drug applications. The time to onset of action of a migraine medication is very important. If the medication is delivered in time, it can cut a migraine off at its knees and save the patient from an ugly 12–36 hours. On the other hand, if a patient pops a pill and it takes 45 minutes to kick in, a migraine may get the foothold it needs to overwhelm the medication.

IntelGenx is moving rizatriptan onto a thin film strip. The time to onset of action for a drug delivered via sublingual strip is much faster than for the pill form. Annual sales of prescription migraine drugs on a global basis are probably more than $5B; annual sales of rizatriptan were over $600M in 2011. If IntelGenx can introduce a better form of the drug, cutting the time to onset of action in half or more—or even if the film cuts it by a third—doctors and patients will be very attracted. IntelGenx's drug could gain market share quickly in the migraine medication area. In another example, the company is moving an erectile dysfunction drug onto a strip. You can imagine reasons you may want quicker onset of action with that.

The bottom line from an investor perspective is that, as of the close on Aug. 3, 2012, the stock is lower than it was before the company's antidepressant received FDA approval on Nov. 11, 2011; lower than it was before its December 2011 codevelopment and commercialization deal with Par Pharmaceutical Inc.; and lower than it was before the announcement of a commercialization partner for its antidepressant. I would argue that at $0.80 or lower, the only thing an investor is paying for is the antidepressant, meaning that you are getting the entire thin-film delivery platform and eight pipeline drugs for free.

I suggest that investors check out the analyst report published two weeks ago by Ram Selvaraju of Aegis Capital Corp., initiating coverage on IntelGenx with a $2.50/share, 18-month target. Ram is known as one of the few analysts willing to pick up coverage on sub-$50M market cap companies—as long as he thinks that he can make investors significant returns. One of his more notable sub-$50M initiations was Amarin, back in 2009, when it had a market cap of about $40M.

DennisMape
07-14-2015,
Good dd. I agree and beleive this could at least break $1.00 by end of year(with good news)imo I've been in since July .52 and waiting for faster uppppcccdaisy.
News will dew rr.

DennisSels
07-15-2015,
Intelgenx has a unique Potency drug which works much faster than all ED drugs on the Market like ****** ,Cialis and Levitra . IGXT?s Potency Drug alone is worth more than $2++ per Share .

Partnership is Imminent and NDA filing for this Potency drug is planned for 1H 2013 .

Tadalafil film – indicated for Erectile Dysfunction

IntelGenx’ tadalafil film is a new product opportunity formulated using VersaFilm™, IntelGenx’ proprietary thin film technology. Tadalafil is one of the three major PDE5 inhibitors in the erectile dysfunction market. Compared with the competitors, tadalafil shows longer duration of action and less food effect. IntelGenx’ tadalafil film offers an improved discrete dosage form that does not require water intake. IntelGenx tadalafil film formulations have been tested in various clinical trials to improve the pharmacokinetics and optimize the formulation. The latest formulation is planned to be tested in a pilot study in Q4 2012. IntelGenx is currently looking for a partnership or alliance opportunity to complete development and commercialize the tadalafil film.

---

Wafer ****** For Instant Results

One of the big challenges for erectile dysfunction medicine manufacturers is to quicken the time between the application of the medicine and its response. Men want instant results when they take ******, Cialis or Levitra and complain that having to wait as much as thirty minutes before the active ingredient is effective can burst the bubble of spontaneity and passion which are often essential requirements of good sex.

Well a solution could be at hand following research done by a Canadian research company called IntelGenx who have developed wafers [like the common breath freshness ones] that are designed to melt on your tongue which they say will get the medicine into your bloodstream around 30% faster than by using conventional tablets.

IntelGenx say that because the mouth is lined with tiny blood vessels applying the wafer ****** here can give a very fast application of the drug directly into the bloodstream.

Sometimes men complain that if they have eaten a large meal it can take an even longer time for the ******, Cialis and Levitra to take effect. If on the other hand they made use of erectile dysfunction medication in a wafer form applied directly to the mouth and therefore bypassing their digestive system this problem would disappear.

Using a wafer type of ****** would also mean that you wouldn't have to go and get a glass of water in the middle of a passionate encounter in order to swallow your pill. Wafer ****** would be a much more discreet application of impotence medication .

dgskbciw08
07-16-2015,
IntelGenx (IGXT) receives Analyst coverage from AEGIS - Buy Rating with Price Target !!!

Initiating Coverage. We are initiating coverage on IntelGenx Technologies Corp., an emerging specialty pharmaceuticals company, with a Buy rating and an 18-month price target of $2.50 per share. In our view, IntelGenx is an extremely undervalued company with a highly risk-mitigated product candidate pipeline, three valuable technology platforms, and a very capital-efficient business model. The firm has demonstrated the ability to develop drug candidates rapidly using the so-called 505(b)(2) regulatory pathway and has even managed to get one of its agents approved by the FDA in the U.S. without any help from a partner, which is unheard-of for firms of this size.

Multiple Value Drivers Ahead. We believe that, with a market cap of under $32 mm and potential to achieve cash flow positive status in 2013, this company should be the focus of investor attention. Since the firm utilizes the 505(b)(2) pathway, all of its drug candidates are based on well-known agents that have already been approved in some other form. This mitigates risk and also allows IntelGenx to move pipeline candidates from concept into the clinic at an unprecedented rate.

Unwarranted Valuation Discrepancy. We note that IntelGenx's current enterprise value is lower than the aggregate value of the milestone payments due to the firm on future sales of Forfivo?. Further, we would point out that even though IntelGenx closed 1Q 2013 with only $3.5mm in cash, the firm uses so little cash to fund operations that we do not project any near-term financing need.